Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
Minimally invasive and robotic esophagectomy: state of the art.

Journal of visualized surgery

Taurchini M, Cuttitta A.
PMID: 29078685
J Vis Surg. 2017 Sep 14;3:125. doi: 10.21037/jovs.2017.08.23. eCollection 2017.

Esophageal cancer is the eight most common cancer in the world and surgical resection remains the gold standard not only in providing the optimal chance for cure but also the best palliation for dysphagia. Esophagectomy is a complex operation...

Cite
Taurchini M, Cuttitta A. Minimally invasive and robotic esophagectomy: state of the art. J Vis Surg. 2017;3:125doi: 10.21037/jovs.2017.08.23.
Taurchini, M., & Cuttitta, A. (2017). Minimally invasive and robotic esophagectomy: state of the art. Journal of visualized surgery, 3125. https://doi.org/10.21037/jovs.2017.08.23
Taurchini, Marco, and Cuttitta, Antonello. "Minimally invasive and robotic esophagectomy: state of the art." Journal of visualized surgery vol. 3 (2017): 125. doi: https://doi.org/10.21037/jovs.2017.08.23
Taurchini M, Cuttitta A. Minimally invasive and robotic esophagectomy: state of the art. J Vis Surg. 2017 Sep 14;3:125. doi: 10.21037/jovs.2017.08.23. eCollection 2017. PMID: 29078685; PMCID: PMC5639027.
Copy Download .nbib Format: NLM
Esophageal Achalasia: Predictive Value of Preoperative Resting Pressure of LES Correlated with Type of Fundoplication.

The Eurasian journal of medicine

Tancredi A, Cuttitta A, Scaramuzzi R, Scaramuzzi G, Taurchini M.
PMID: 28416923
Eurasian J Med. 2017 Feb;49(1):1-6. doi: 10.5152/eurasianjmed.2017.16151.

OBJECTIVE: The aim of the present study is to show the predictive value of the preoperative resting pressure of the lower esophageal sphincter (LES) correlated with the type of fundoplication (Nissen or Dor) after Heller myotomy in our series.MATERIALS...

Cite
Tancredi A, Cuttitta A, Scaramuzzi R, et al. Esophageal Achalasia: Predictive Value of Preoperative Resting Pressure of LES Correlated with Type of Fundoplication. Eurasian J Med. 2017;49(1):1-6doi: 10.5152/eurasianjmed.2017.16151.
Tancredi, A., Cuttitta, A., Scaramuzzi, R., Scaramuzzi, G., & Taurchini, M. (2017). Esophageal Achalasia: Predictive Value of Preoperative Resting Pressure of LES Correlated with Type of Fundoplication. The Eurasian journal of medicine, 49(1), 1-6. https://doi.org/10.5152/eurasianjmed.2017.16151
Tancredi, Antonio, et al. "Esophageal Achalasia: Predictive Value of Preoperative Resting Pressure of LES Correlated with Type of Fundoplication." The Eurasian journal of medicine vol. 49,1 (2017): 1-6. doi: https://doi.org/10.5152/eurasianjmed.2017.16151
Tancredi A, Cuttitta A, Scaramuzzi R, Scaramuzzi G, Taurchini M. Esophageal Achalasia: Predictive Value of Preoperative Resting Pressure of LES Correlated with Type of Fundoplication. Eurasian J Med. 2017 Feb;49(1):1-6. doi: 10.5152/eurasianjmed.2017.16151. PMID: 28416923; PMCID: PMC5389485.
Copy Download .nbib Format: NLM
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.

Journal of thoracic disease

Marchetti A, Di Lorito A, Buttitta F.
PMID: 29312678
J Thorac Dis. 2017 Dec;9(12):4863-4866. doi: 10.21037/jtd.2017.11.105.

No abstract available.

Cite
Marchetti A, Di Lorito A, Buttitta F. Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle. J Thorac Dis. 2017;9(12):4863-4866doi: 10.21037/jtd.2017.11.105.
Marchetti, A., Di Lorito, A., & Buttitta, F. (2017). Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle. Journal of thoracic disease, 9(12), 4863-4866. https://doi.org/10.21037/jtd.2017.11.105
Marchetti, Antonio, et al. "Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle." Journal of thoracic disease vol. 9,12 (2017): 4863-4866. doi: https://doi.org/10.21037/jtd.2017.11.105
Marchetti A, Di Lorito A, Buttitta F. Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle. J Thorac Dis. 2017 Dec;9(12):4863-4866. doi: 10.21037/jtd.2017.11.105. PMID: 29312678; PMCID: PMC5756957.
Copy Download .nbib Format: NLM
Circulating levels of cytokines, chemokines and growth factors in patients with achalasia.

Biomedical reports

Panza A, Fontana A, Palmieri O, Merla A, Copetti M, Cuttitta A, Biscaglia G, Gentile A, Andriulli A, Latiano A.
PMID: 34631047
Biomed Rep. 2021 Nov;15(5):92. doi: 10.3892/br.2021.1468. Epub 2021 Sep 10.

Idiopathic achalasia is a disease that is characterized by the absence of peristalsis and incomplete relaxation of the lower esophageal sphincter, which is accompanied by dysphagia, regurgitation, chest pain and weight loss. The role of inflammatory infiltrates in the...

Cite
Panza A, Fontana A, Palmieri O, et al. Circulating levels of cytokines, chemokines and growth factors in patients with achalasia. Biomed Rep. 2021;15(5):92doi: 10.3892/br.2021.1468.
Panza, A., Fontana, A., Palmieri, O., Merla, A., Copetti, M., Cuttitta, A., Biscaglia, G., Gentile, A., Andriulli, A., & Latiano, A. (2021). Circulating levels of cytokines, chemokines and growth factors in patients with achalasia. Biomedical reports, 15(5), 92. https://doi.org/10.3892/br.2021.1468
Panza, Anna, et al. "Circulating levels of cytokines, chemokines and growth factors in patients with achalasia." Biomedical reports vol. 15,5 (2021): 92. doi: https://doi.org/10.3892/br.2021.1468
Panza A, Fontana A, Palmieri O, Merla A, Copetti M, Cuttitta A, Biscaglia G, Gentile A, Andriulli A, Latiano A. Circulating levels of cytokines, chemokines and growth factors in patients with achalasia. Biomed Rep. 2021 Nov;15(5):92. doi: 10.3892/br.2021.1468. Epub 2021 Sep 10. PMID: 34631047; PMCID: PMC8461322.
Copy Download .nbib Format: NLM
Perceived Barriers to the De-implementation of Routine Preoperative History & Physicals Preceding Low-Risk Ambulatory Procedures: A Qualitative Study of Surgeon Perspectives.

The Journal of surgical research

Baskin AS, Mansour AI, Kawakibi AR, Das PJ, Rios AE, Miller J, Cuttitta A, Lahti H, Dossett LA.
PMID: 34736128
J Surg Res. 2022 Feb;270:359-368. doi: 10.1016/j.jss.2021.07.043. Epub 2021 Nov 01.

BACKGROUND: For patients undergoing surgery at an Ambulatory Surgical Center, recent changes to Centers for Medicare and Medicaid Services policy allow for the omission of a 30-day preoperative History and Physical (H&P). Preoperative H&Ps for low-risk surgery may contribute...

Cite
Baskin AS, Mansour AI, Kawakibi AR, et al. Perceived Barriers to the De-implementation of Routine Preoperative History & Physicals Preceding Low-Risk Ambulatory Procedures: A Qualitative Study of Surgeon Perspectives. J Surg Res. 2021;270:359-368doi: 10.1016/j.jss.2021.07.043.
Baskin, A. S., Mansour, A. I., Kawakibi, A. R., Das, P. J., Rios, A. E., Miller, J., Cuttitta, A., Lahti, H., & Dossett, L. A. (2022). Perceived Barriers to the De-implementation of Routine Preoperative History & Physicals Preceding Low-Risk Ambulatory Procedures: A Qualitative Study of Surgeon Perspectives. The Journal of surgical research, 270359-368. https://doi.org/10.1016/j.jss.2021.07.043
Baskin, Alison S, et al. "Perceived Barriers to the De-implementation of Routine Preoperative History & Physicals Preceding Low-Risk Ambulatory Procedures: A Qualitative Study of Surgeon Perspectives." The Journal of surgical research vol. 270 (2022): 359-368. doi: https://doi.org/10.1016/j.jss.2021.07.043
Baskin AS, Mansour AI, Kawakibi AR, Das PJ, Rios AE, Miller J, Cuttitta A, Lahti H, Dossett LA. Perceived Barriers to the De-implementation of Routine Preoperative History & Physicals Preceding Low-Risk Ambulatory Procedures: A Qualitative Study of Surgeon Perspectives. J Surg Res. 2022 Feb;270:359-368. doi: 10.1016/j.jss.2021.07.043. Epub 2021 Nov 01. PMID: 34736128.
Copy Download .nbib Format: NLM
Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines.

Cancers

Nicosia A, Cavallaro G, Costa S, Utzeri MA, Cuttitta A, Giammona G, Mauro N.
PMID: 33113761
Cancers (Basel). 2020 Oct 25;12(11). doi: 10.3390/cancers12113114.

BACKGROUND: Engineered luminescent carbon nanodots (CDs) are appealing nanomaterials for cancer image-guided photothermal therapy combining near infrared (NIR)-triggered hyperthermia, imaging, and drug delivery in a single platform for efficient killing of cancer cells. This approach would allow eliciting synergistic...

Cite
Nicosia A, Cavallaro G, Costa S, et al. Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113114.
Nicosia, A., Cavallaro, G., Costa, S., Utzeri, M. A., Cuttitta, A., Giammona, G., & Mauro, N. (2020). Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines. Cancers, 12(11), . https://doi.org/10.3390/cancers12113114
Nicosia, Aldo, et al. "Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113114
Nicosia A, Cavallaro G, Costa S, Utzeri MA, Cuttitta A, Giammona G, Mauro N. Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines. Cancers (Basel). 2020 Oct 25;12(11). doi: 10.3390/cancers12113114. PMID: 33113761; PMCID: PMC7692354.
Copy Download .nbib Format: NLM
[Adrenomedullin: a new peptide with many clinical implications].

Anales del sistema sanitario de Navarra

Martínez A, Garayoa M, Pío R, Miller MJ, Cuttitta F.
PMID: 12886331
An Sist Sanit Navar. 1999 Sep-Dec;22(3):307-15. doi: 10.23938/ASSN.0702.

No abstract available.

Cite
Martínez A, Garayoa M, Pío R, et al. Adrenomedulina: un nuevo péptido con numerosas implicaciones clínicas. [Adrenomedullin: a new peptide with many clinical implications]. An Sist Sanit Navar. 1999;22(3):307-15doi: 10.23938/ASSN.0702.
Martínez, A., Garayoa, M., Pío, R., Miller, M. J., & Cuttitta, F. (1999). Adrenomedulina: un nuevo péptido con numerosas implicaciones clínicas. [Adrenomedullin: a new peptide with many clinical implications]. Anales del sistema sanitario de Navarra, 22(3), 307-15. https://doi.org/10.23938/ASSN.0702
Martínez, A, et al. "Adrenomedulina: un nuevo péptido con numerosas implicaciones clínicas." [Adrenomedullin: a new peptide with many clinical implications]. Anales del sistema sanitario de Navarra vol. 22,3 (1999): 307-15. doi: https://doi.org/10.23938/ASSN.0702
Martínez A, Garayoa M, Pío R, Miller MJ, Cuttitta F. Adrenomedulina: un nuevo péptido con numerosas implicaciones clínicas. [Adrenomedullin: a new peptide with many clinical implications]. An Sist Sanit Navar. 1999 Sep-Dec;22(3):307-15. doi: 10.23938/ASSN.0702. Spanish. PMID: 12886331.
Copy Download .nbib Format: NLM
[No title available]

Diagnostics (Basel, Switzerland)

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
PMID: 31600986
Diagnostics (Basel). 2019 Oct 09;9(4). doi: 10.3390/diagnostics9040146.

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for

Cite
Capoluongo E, La Verde N, Barberis M, et al. . Diagnostics (Basel). 2019;9(4)doi: 10.3390/diagnostics9040146.
Capoluongo, E., La Verde, N., Barberis, M., Bella, M. A., Buttitta, F., Carrera, P., Colombo, N., Cortesi, L., Gion, M., Guarneri, V., Lorusso, D., Marchetti, A., Marchetti, P., Normanno, N., Pasini, B., Pensabene, M., Pignata, S., Radice, P., Ricevuto, E., Sapino, A., Tagliaferri, P., Tassone, P., Trevisiol, C., Truini, M., Varesco, L., Russo, A., & Gori, S. (2019). . Diagnostics (Basel, Switzerland), 9(4), . https://doi.org/10.3390/diagnostics9040146
Capoluongo, Ettore, et al. "." Diagnostics (Basel, Switzerland) vol. 9,4 (2019). doi: https://doi.org/10.3390/diagnostics9040146
Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S. . Diagnostics (Basel). 2019 Oct 09;9(4). doi: 10.3390/diagnostics9040146. PMID: 31600986; PMCID: PMC6963957.
Copy Download .nbib Format: NLM
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of .

Oncotarget

Buttitta F, Felicioni L, Lorito AD, Cortellini A, Irtelli L, Brocco D, Marino PD, Traisci D, D'Ostilio N, Paolo AD, Malorgio F, Assalone P, Felice SD, Fabbri F, Cianci G, Tursi M, Marchetti A.
PMID: 32215186
Oncotarget. 2020 Mar 17;11(11):982-991. doi: 10.18632/oncotarget.27517. eCollection 2020 Mar 17.

In Non-Small-Cell Lung Cancer (NSCLC) patients treated with Tyrosine Kinase-Inhibitors (TKIs) therapy, the emergence of acquired resistance can be investigated by plasma monitoring of circulating tumor DNA (ctDNA). A series of 116 patients with

Cite
Buttitta F, Felicioni L, Lorito AD, et al. Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of . Oncotarget. 2020;11(11):982-991doi: 10.18632/oncotarget.27517.
Buttitta, F., Felicioni, L., Lorito, A. D., Cortellini, A., Irtelli, L., Brocco, D., Marino, P. D., Traisci, D., D'Ostilio, N., Paolo, A. D., Malorgio, F., Assalone, P., Felice, S. D., Fabbri, F., Cianci, G., Tursi, M., & Marchetti, A. (2020). Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of . Oncotarget, 11(11), 982-991. https://doi.org/10.18632/oncotarget.27517
Buttitta, Fiamma, et al. "Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of ." Oncotarget vol. 11,11 (2020): 982-991. doi: https://doi.org/10.18632/oncotarget.27517
Buttitta F, Felicioni L, Lorito AD, Cortellini A, Irtelli L, Brocco D, Marino PD, Traisci D, D'Ostilio N, Paolo AD, Malorgio F, Assalone P, Felice SD, Fabbri F, Cianci G, Tursi M, Marchetti A. Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of . Oncotarget. 2020 Mar 17;11(11):982-991. doi: 10.18632/oncotarget.27517. eCollection 2020 Mar 17. PMID: 32215186; PMCID: PMC7082112.
Copy Download .nbib Format: NLM
Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells.

Scientific reports

Takahashi H, Yumoto K, Yasuhara K, Nadres ET, Kikuchi Y, Buttitta L, Taichman RS, Kuroda K.
PMID: 31767898
Sci Rep. 2019 Nov 25;9(1):17455. doi: 10.1038/s41598-019-53859-y.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Takahashi H, Yumoto K, Yasuhara K, et al. Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells. Sci Rep. 2019;9(1):17455doi: 10.1038/s41598-019-53859-y.
Takahashi, H., Yumoto, K., Yasuhara, K., Nadres, E. T., Kikuchi, Y., Buttitta, L., Taichman, R. S., & Kuroda, K. (2019). Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells. Scientific reports, 9(1), 17455. https://doi.org/10.1038/s41598-019-53859-y
Takahashi, Haruko, et al. "Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells." Scientific reports vol. 9,1 (2019): 17455. doi: https://doi.org/10.1038/s41598-019-53859-y
Takahashi H, Yumoto K, Yasuhara K, Nadres ET, Kikuchi Y, Buttitta L, Taichman RS, Kuroda K. Author Correction: Anticancer polymers designed for killing dormant prostate cancer cells. Sci Rep. 2019 Nov 25;9(1):17455. doi: 10.1038/s41598-019-53859-y. PMID: 31767898; PMCID: PMC6877596.
Copy Download .nbib Format: NLM
Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study.

BMC pulmonary medicine

Scichilone N, Antonelli Incalzi R, Blasi F, Schino P, Cuttitta G, Zullo A, Ori A, Canonica GW.
PMID: 31801499
BMC Pulm Med. 2019 Dec 04;19(1):235. doi: 10.1186/s12890-019-0992-6.

Following publication of the original article [1], the authors flagged that the article had been provided with the names of the authors (not including the STORICO study group) in the wrong order: the 'Given Names' and Family Names' were...

Cite
Scichilone N, Antonelli Incalzi R, Blasi F, et al. Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulm Med. 2019;19(1):235doi: 10.1186/s12890-019-0992-6.
Scichilone, N., Antonelli Incalzi, R., Blasi, F., Schino, P., Cuttitta, G., Zullo, A., Ori, A., Canonica, G. W. (2019). Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC pulmonary medicine, 19(1), 235. https://doi.org/10.1186/s12890-019-0992-6
Scichilone, Nicola, et al. "Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study." BMC pulmonary medicine vol. 19,1 (2019): 235. doi: https://doi.org/10.1186/s12890-019-0992-6
Scichilone N, Antonelli Incalzi R, Blasi F, Schino P, Cuttitta G, Zullo A, Ori A, Canonica GW. Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulm Med. 2019 Dec 04;19(1):235. doi: 10.1186/s12890-019-0992-6. PMID: 31801499; PMCID: PMC6891964.
Copy Download .nbib Format: NLM
Characterization of Translationally Controlled Tumour Protein from the Sea Anemone Anemonia viridis and Transcriptome Wide Identification of Cnidarian Homologues.

Genes

Nicosia A, Bennici C, Biondo G, Costa S, Di Natale M, Masullo T, Monastero C, Ragusa MA, Tagliavia M, Cuttitta A.
PMID: 29324689
Genes (Basel). 2018 Jan 11;9(1). doi: 10.3390/genes9010030.

Gene family encoding translationally controlled tumour protein (TCTP) is defined as highly conserved among organisms; however, there is limited knowledge of non-bilateria. In this study, the first TCTP homologue from anthozoan was characterised in the Mediterranean Sea anemone,

Cite
Nicosia A, Bennici C, Biondo G, et al. Characterization of Translationally Controlled Tumour Protein from the Sea Anemone Anemonia viridis and Transcriptome Wide Identification of Cnidarian Homologues. Genes (Basel). 2018;9(1)doi: 10.3390/genes9010030.
Nicosia, A., Bennici, C., Biondo, G., Costa, S., Di Natale, M., Masullo, T., Monastero, C., Ragusa, M. A., Tagliavia, M., & Cuttitta, A. (2018). Characterization of Translationally Controlled Tumour Protein from the Sea Anemone Anemonia viridis and Transcriptome Wide Identification of Cnidarian Homologues. Genes, 9(1), . https://doi.org/10.3390/genes9010030
Nicosia, Aldo, et al. "Characterization of Translationally Controlled Tumour Protein from the Sea Anemone Anemonia viridis and Transcriptome Wide Identification of Cnidarian Homologues." Genes vol. 9,1 (2018). doi: https://doi.org/10.3390/genes9010030
Nicosia A, Bennici C, Biondo G, Costa S, Di Natale M, Masullo T, Monastero C, Ragusa MA, Tagliavia M, Cuttitta A. Characterization of Translationally Controlled Tumour Protein from the Sea Anemone Anemonia viridis and Transcriptome Wide Identification of Cnidarian Homologues. Genes (Basel). 2018 Jan 11;9(1). doi: 10.3390/genes9010030. PMID: 29324689; PMCID: PMC5793182.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries